Everitt, Hazel A., Moss-Morris, Rona E., Sibelli, Alice, Tapp, Laura, Coleman, Nicholas S., Yardley, Lucy, Smith, Peter W. and Little, Paul S.
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website (MIBS trial).
BMC Gastroenterology, 10, (136) (doi:10.1186/1471-230X-10-136).
Background: IBS affects 10-22% of the UK population. Abdominal pain, bloating and altered bowel habit affect
quality of life, social functioning and time off work. Current GP treatment relies on a positive diagnosis, reassurance,lifestyle advice and drug therapies, but many suffer ongoing symptoms. A recent Cochrane review highlighted the lack of research evidence for IBS drugs. Neither GPs, nor patients have good evidence to inform prescribing decisions. However, IBS drugs are widely used: In 2005 the NHS costs were nearly £10 million for mebeverine and over £8 million for fibre-based bulking agents. CBT and self-management can be helpful, but poor availability in the NHS restricts their use. We have developed a web-based CBT selfmanagement programme, Regul8, based on an existing evidence based self-management manual and in partnership with patients. This could increase access with minimal increased costs.
Methods/Design: The aim is to undertake a feasibility factorial RCT to assess the effectiveness of the commonly
prescribed medications in UK general practice for IBS: mebeverine (anti-spasmodic) and methylcellulose(bulkingagent)and Regul8, the CBT based self-management website. 135 patients aged 16 to 60 years with IBS symptoms fulfilling Rome III criteria, recruited via GP practices, will be randomised to 1 of 3 levels of the drug condition: mebeverine, methylcellulose or placebo for 6 weeks and to 1 of 3 levels of the website condition, Regul8 with a nurse telephone session and email support, Regul8 with minimal
email support, or no website, thus creating 9 groups.
Outcomes: Irritable bowel symptom severity scale and IBS-QOL will be measured at baseline, 6 and 12 weeks as
the primary outcomes. An intention to treat analysis will be undertaken by ANCOVA for a factorial trial.
Discussion: This pilot will provide valuable information for a larger trial. Determining the effectiveness of
commonly used drug treatments will help patients and doctors make informed treatment decisions regarding drug
management of IBS symptoms, enabling better targeting of treatment. A web-based self-management CBT programme for IBS developed in partnership with patients has the potential to benefit large numbers of patients with low cost to the NHS. Assessment of the amount of email or therapist support required for the website will
enable economic analysis to be undertaken.
Trial Registration: ClinicalTrials.gov Identifier (NCT number): NCT00934973.
Actions (login required)